The Clinical Core of the Arizona ADCC is a consortium of five recruitment sites that function as a? standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500? participants at all stages of the aging-dementia spectrum including 200 normal controls, 100 patients with? mild cognitive impairment (MCI), and 200 with Alzheimer's disease (AD) and other forms of degenerative? dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts.? The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data? management program, and close working relationships with each of the other Cores. It is intended to? capitalize on our multi-institutional collaborative model, address the challenges associated with a multi-site? core, and optimize the utilization of Clinical Core subjects and data in support of the unusually early? detection and tracking of AD, our strengths in brain imaging, cognitive neuroscience, neurogenomics, our? studies of several putative risk factors, and our participation in several national and international? collaboration projects. All subjects undergo standardized diagnostic testing that 1) fulfills strict entrance? criteria, 2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and? genetic measures, 3) incorporates the NACC Uniform Data Set (UDS), and 4) employs culturally sensitive? test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a? biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and? an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for, and participation? in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrolled in the? Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is? not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). The? particular strengths of the Clinical Core include:? 1. catchment areas throughout the state of Arizona based on a novel collaborative model that includes all? major tertiary care referral centers (BNI, MCA, SHRI, VA, UA)? 2. a scientific network of established collaborative relationships between Clinical Core neurologists and? biomedical researchers at all major research institutions in Arizona (and elsewhere)? 3. a Latino outreach program (through the collaborative efforts of the EIT and Clinical Cores) with a target? enrollment of at least 100 dementia/MCI patients and controls? 4. a Native American outreach program (through the collaborative efforts of the EIT and Clinical Cores) that? encourages the participation of Native Americans in the Clinical Core.? 5. ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported? through other funding mechanisms. These cohorts provide unique opportunities to study the transition? between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths? in imaging, genomics, cognitive neuroscience, and other research methods. To address the goals of the? ADCC, subjects and data from independently funded projects are now available as a resource to other? researchers, being used in other studies, and will be followed prospectively using the UDS.?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
2P30AG019610-06
Application #
7163209
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (M1))
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2006-09-15
Budget End
2007-06-30
Support Year
6
Fiscal Year
2006
Total Cost
$484,335
Indirect Cost
Name
Sun Health Research Institute
Department
Type
DUNS #
960181055
City
Sun City
State
AZ
Country
United States
Zip Code
85351
Mahady, Laura; Nadeem, Muhammad; Malek-Ahmadi, Michael et al. (2018) Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. J Alzheimers Dis 62:115-131
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment. J Am Geriatr Soc 66:671-678
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Liu, Li; Caselli, Richard J (2018) Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease. Alzheimers Dement (N Y) 4:602-608
Allen, Mariet; Wang, Xue; Burgess, Jeremy D et al. (2018) Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimers Dement 14:352-366
Zbesko, Jacob C; Nguyen, Thuy-Vi V; Yang, Tao et al. (2018) Glial scars are permeable to the neurotoxic environment of chronic stroke infarcts. Neurobiol Dis 112:63-78
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Subjective Cognitive Impairment and the Broad Autism Phenotype. Alzheimer Dis Assoc Disord 32:284-290
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Salloway, Stephen; Honigberg, Lee A; Cho, William et al. (2018) Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE). Alzheimers Res Ther 10:96

Showing the most recent 10 out of 794 publications